Aprea Therapeutics Reports Third Quarter 2020 Financial Results and Provides Update on Business OperationsGlobeNewsWire • 11/05/20
Aprea Therapeutics to Highlight Changing Treatment Paradigm in MDS as well as Development Pipeline Progress at Virtual R&D Day TodayGlobeNewsWire • 10/30/20
Aprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53reactivation.comGlobeNewsWire • 10/14/20
Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548GlobeNewsWire • 10/07/20
Aprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance ChangesGlobeNewsWire • 09/18/20
Aprea Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on Business OperationsGlobeNewsWire • 08/11/20
Karolinska Development’s portfolio company Aprea Therapeutics expands clinical trial of eprenetapopt for TP53 mutant Acute Myeloid LeukemiaGlobeNewsWire • 07/16/20
Aprea Therapeutics Announces Expansion of Clinical Trial Evaluating Eprenetapopt for the Front-Line Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)GlobeNewsWire • 07/16/20
How Aprea Therapeutics (APRE) Stock Stands Out in a Strong IndustryZacks Investment Research • 07/01/20
Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 (Eprenetapopt) and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia at the 25th European Hematology Association Annual MeetiGlobeNewsWire • 06/12/20
Aprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant Myelodysplastic Syndromes (MDS)GlobeNewsWire • 06/03/20
Aprea Therapeutics Reports First Quarter 2020 Financial Results and Provides Update on Business OperationsGlobeNewsWire • 05/15/20
Aprea Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/26/20
Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 MutationGlobeNewsWire • 01/30/20